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The present study has investigated the effectiveness of staged-preconditioning, in both remote and target organs. After IP the
myocardial release of the biochemical markers including, creatine phosphokinase (CPK), cardiac creatine kinase (CK-MB), cardiac
troponin T (cTnT) and lactate dehydrogenase (LDH) were evaluated in patients who underwent CABG, with and without
staged-preconditioning. Sixty-one patients entered the study; there were 32 patients in the staged-preconditioning group and
29 patients in the control group. All patients underwent on-pump CABG using cardiopulmonary bypass (CPB) techniques. In
the staged-preconditioning group, patients underwent two stages of IP on remote (upper limb) and target organs. Each stage
of preconditioning was carried out by 3 cycles of ischemia and then reperfusion. Serum levels of biochemical markers were
immediately measured postoperatively at 24, 48 and 72 h. Serum CK-MB, CPK and LDH levels were significantly lower in the
staged-preconditioning group than in the control group. The CK-MB release in the staged-preconditioning patients reduced by
51% in comparison with controls over 72 h after CABG. These results suggest that myocardial injury was attenuated by the effect
of three rounds of both remote and target organ IP.
1. Introduction
New treatment strategies are required to reduce myocardial
injury and improve clinical outcomes in patients with
coronary heart disease (CHD), the leading cause of death
worldwide.
The protective effects of ischemic preconditioning (IP)
on human heart after cardiac surgeries are well defined
[1]. Initially, the positive effect of short periods of ischemia
to limit infarct size was referred to IP [2]. It was then
established to have beneficial effects on ischemia and reper-
fusion induced arrhythmia and on myocardial stunning
[3, 4]. Furthermore, it has been suggested that IP reduces
postoperative inotropic requirements and has a preventive
role in postoperative myocardial dysfunction [5, 6].
Ischemic preconditioning can be mechanical or pharma-
cological. Direct mechanical preconditioning in which the
major organ is exposed to brief ischemia prior to prolonged
ischemia has the benefit of reducing ischemia-reperfusion
injury (IRJ). Remote preconditioning is a brief ischemia of
one organ which has been shown to confer protection on
distant organs without direct stress to the target organ [7].
Remote ischemic preconditioning (RIPC) can limit
myocardial infarction size that has been successfully applied
to the protection of other noncardiac organs against
ischemia-reperfusion injury [8]. Both types of precondition
have their own advantages. In this regard, we have investi-
gated the effectiveness of staged-preconditioning including
both remote and target organ ischemic preconditioning on
patients undergoing on-pump coronary artery bypass graft-
ing (CABG) using cardiopulmonary bypass (CPB) method.
The present study evaluated the myocardial release of the
cardiac biochemical markers including, creatine phospho-
kinase (CPK), cardiac creatine kinase (CK-MB), cardiac
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troponin T (cTnT), and lactate dehydrogenase (LDH)
in patients undergoing CABG, with and without staged-
preconditioning. These biochemical markers are widely used
to detect postoperative myocardial damage during CABG
surgery [9].
2. Patients and Methods
This randomized controlled trial was carried out at Imam
khomeini Hospital, Ardabil, Iran. An ethics committee of
Human research of Ardabil University of Medical Sciences
approved the study. Measurement of biochemical markers
after cardiovascular surgeries is routine and all patients gave
an informed consent before enrolment.
Patients. Sixty-one patients (male/female: 33/28, mean
age: 58 ± 10 years), who underwent first-time elective CABG
entered the study; there were 32 patients in the staged
preconditioning group and 29 patients in the control group.
Patients were excluded if they had concomitant disease of
heart valves, pulmonary hypertension, myocardial infarction
(MI), and history of unstable angina within the past two
months and preoperative inotropic support or any kind of
mechanical assist device.
Surgical Techniques. All patients underwent on-pump
coronary artery bypass grafting (CABG) using standard
cardiopulmonary bypass (CPB) techniques with antegrade
and retrograde bloody cardioplegia. The anesthetic and
CABG techniques were the same in all cases. In the staged-
preconditioning group, patients underwent two stages of
ischemic preconditioning at remote (upper limb) and target
organs. After induction of anesthesia, remote ischemic
preconditioning (RIPC) was carried out by 3 cycles of 5min
left upper arm ischemia by inflation of a blood pressure
cuff to 200mmHg and then reperfusion. First ischemia
before preparation of the patients, second ischemia after
sternotomy, and third ischemia was achieved just performing
left internal mammary artery (LIMA). Second stage of
preconditioning was carried out on the target organ in 3
cycles too. During each phase the pressure was established
between 30 to 40mmHg for 1.5min. First ischemia after
cannulation and just before CPB, second phase after CPB and
before cardioplegia perfusion, and third phase of ischemia
was induced just performing declamping.
Blood Sampling and Biochemical Markers. Venous blood
samples were drown from each patient in two groups
postoperatively at 24, 48, and 72 h and analyzed separately for
CPK, its cardiac isoenzyme (CK-MB), cTnT, and LDH. All
samples were immediately centrifuged for 10 min at 3000 g
(rcf), and serum enzyme activities were measured at 37◦C.
SerumCPK, CK-MB, and LDH determinations were done by
means of test kits (Pars azmoon, Iran) using an autoanalyzer
system (BT 3000, Italy). Determination of serum cTnT was
performed by means of test kit (Elecsys 2010, Switzerland)
using electrochemiluminescence immunoassay (ECLIA).
The reference interval for CPK and LDH is 24–170 u/l
and 150–500 u/l, respectively. The upper limits of the
reference interval for the CK-MB and cTnT assays are 24 u/l
and 0.01 ng/l, respectively.
Statistical Analysis. Statistical analysis was performed
using a graph and data analysis software package (SigmaPlot
11.0, Systat Software, Inc.). Data are presented as mean± SD,
except in figures where error bars represent SEM. ANOVA
tests followed by the pairwise Student-Newman-Keuls test
for multiple comparisons were performed to check for
differences. P value less than 0.05 was considered significant.
3. Results
There was no recorded case of mortality or morbidity in
these two groups of patients. There were no significant
differences between the two groups with regard to pre-
operative parameters such as sex, age, and body surface
area. Cumulative cardiac biochemical marker release was
calculated as the mean net release at all 3 measuring time
points after operation.
Serum concentrations of these biochemical markers
increased postoperatively and reached a peak level at 48 h
after operation in both groups, except for cTnT in the control
group that had a peak level at 24 hrs after surgery (Figure 1).
The concentration of CPK, CK-MB, and LDH rose
significantly in the control group within 24, 48, and 72 h
compared with the baseline values obtained from staged-
precondition group at the same time points (Figures 2, 3,
and 4). Levels of CK-MB postoperatively were markedly
greater in the control patients as compared with the staged
preconditioning group (P = 0.001 in three time points)
indicating greater myocardial injury in controls (Figure 3).
The CK-MB release in the staged preconditioning patients
reduced by 51% in comparison with controls over 72 h after
CABG.
In contrast to CPK, CK-MB, and LDH, the difference
between control and staged preconditioning groups release
values for cTnT at 48 and 72 h after operation was not
significant. The rate of increase for cTnT at 24 h was
significantly higher (P = 0.04) than that at 48 and 72 hrs in
the control group compared with the staged preconditioning
group (Figure 1).
4. Discussion
It has been shown that the direct application of an IP
stimulus protects patients against irreversible myocardial
injury [10]. The use of IP with repeated cycles of ischemic
stimuli has been proposed to ensure the protective effects
[11]. It became evident that RIPC provides an easy and
safe method of increasing myocardial surgeries [12]. RIPC
with transient upper limb ischemia and reperfusion were
shown to reduce myocardial injury in patients undergoing
CABG with intermittent coldblood cardioplegia for myocar-
dial protection [12, 13]. Each kind of preconditioning by
inducing brief ischemia before operation increases the body’s
resistance and has a protective effect after surgery [14, 15]. In
this regard, preliminary studies have not been investigated
the concomitant application and effectiveness of remote and
target organ IP in patients undergoing CABG.
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Figure 1: Cardiac troponin t (cTnT) concentration in control and
staged preconditioning groups, 24 h, 48 h, and 72 h after CABG. The
differences in the median values among the control and case groups
are greater than would be expected by chance; there is a statistically
significant difference, all pairwise multiple comparisons showed P
value less than 0.05.
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Figure 2: Creatine phosphokinase (CPK) concentration in control
and staged preconditioning groups, 24 h, 48 h, and 72 h after CABG,
all pairwise multiple comparisons showed P value less than 0.05.
In this study we have evaluated the effect of staged
preconditioning on the release of cardiac biochemical mark-
ers in patients undergoing CABG. The novel and unique
approach of this study was to measure lower levels of
these biochemical markers in patients underwent staged
preconditioning. In this study serum CK-MB, CPK, and
LDH levels were significantly lower in staged preconditioning
group than in the control group. We have demonstrated that
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Figure 3: Cardiac creatine kinase (CK-MB) concentration in
control and staged preconditioning groups, 24 h, 48 h, and 72 h after
CABG, all pairwise multiple comparisons showed P value less than
0.05.
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Figure 4: Lactate dehydrogenase (LDH) concentration in control
and staged preconditioning groups, 24 h, 48 h, and 72 h after CABG,
all pairwise multiple comparisons showed P value less than 0.05.
leakage of CK-MB, CPK, LDH, and cTnT were inhibited
to varying degrees in the staged preconditioning group at
several postoperative time points compared to the control
group. The high levels of CK-MB in control patients com-
pared with staged preconditioning patients were remarkable.
In our study, 51% reduction of CK-MB release in staged
preconditioning group was achieved over 72 h after CABG.
These results suggest that myocardial injury was attenuated
by the effect of three rounds of both remote and target
organs IP. Consequently, the higher levels of biochemical
markers in the control group can be interpreted as reflecting
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a greater degree of myocardial injury. The results of this study
indicate that better protection after CABG can be explained
by the overlap of the two widows of protection derived from
the two types of IP treatments. These findings underscore
the effectiveness and protective effects of the application of
IP methods in both remote and target organs. Whether or
not such protection by staged preconditioning has beneficial
impact on patient’s short- and long-term outcome will have
to be elucidated in the future large-scale studies.
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